Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768671 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by MoonLake Immunotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
- 18
- Study locations
NCT06768671: Recruiting Phase 3 study of Hidradenitis Suppurativa, sponsored by MoonLake Immunotherapeutics.
NCT06768671 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by MoonLake Immunotherapeutics. The registered enrollment target is 35 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (94% lower). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06768671, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by MoonLake Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Primary Outcome
PK (trough concentrations) of sonelokimab over 24 weeks of treatment
Conditions Studied
Interventions
- DRUG Sonelokimab
Study Locations (18)
Texas
- Clinical Site - Dallas
- Clinical Site - Dallas
- Clinical Site - San Antonio
Florida
- Clinical Site - Hollywood
- Clinical Site - Miami
Georgia
- Clinical Site - Macon
- Clinical Site - Sandy Springs
Arkansas
- Clinical Site - North Little Rock
California
- Clinical Site - Stanford
District of Columbia
- Clinical Site - Washington D.C.
Illinois
- Clinical Site - Chicago
Indiana
- Clinical Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-03-27 |
| Phase | Phase 3 |
What NCT06768671 shows while recruiting
NCT06768671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Sonelokimab is the first listed.
NCT06768671 lists 18 locations in 14 states (Texas, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT06768671 about?
NCT06768671 is a clinical study titled "An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)". This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
What is the current status of trial NCT06768671?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2024-12-30. Estimated completion is 2026-03-27.
What conditions does trial NCT06768671 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06768671?
The interventions under investigation include: Sonelokimab (DRUG).
Who is sponsoring clinical trial NCT06768671?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06768671 being conducted?
This trial has 18 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06768671's enrollment target sits among peer trials
35 36th of 52 higher than 17 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI